{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000053","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.807178+00:00","generated_at":"2026-05-17T20:32:16.653524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised","bullets":["Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.","Qelbree net sales $77.6M (+31% YoY); GOCOVRI net sales $36.7M (+16% YoY); 225k IQVIA prescriptions.","Adjusted operating earnings (non-GAAP) $40.9M; operating income $12.1M; raising FY 2025 guidance.","Closed Sage Therapeutics acquisition on July 31, adding ZURZUVAE; ONAPGO launch: 750+ enrollment forms."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000053","json":"https://secwatch.observer/filing/0001356576-25-000053.json","markdown":"https://secwatch.observer/filing/0001356576-25-000053.md","text":"https://secwatch.observer/filing/0001356576-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/0001356576-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/supn-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:32:16.653524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}